New Providence research published in Nature-Precision Oncology finds that in head and neck cancer, researchers found that two specific immune responsepatterns—called Activation and Infiltration—can better predict who will benefit from immunotherapy. Patients whose tumors showed both patterns responded best to treatment and lived longer. These findings, confirmed in multiple patient groups, suggest using combined biomarkers is more effective than relying on a single one.
